NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) („NeuroSense“), a late-stage clinical biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Company received formal written notice from The Nasdaq Stock Market LLC („Nasdaq“) that the Company has regained compliance with Nasdaq’s stockholders‘ equity requirement („Equity Requirement“) set forth in Nasdaq Listing Rule 5550(b)(1). The Company’s Ordinary Shares will continue to be listed and trade on The Nasdaq Capital Market under the symbol „NRSN“.
This confirmation follows the Company’s successful efforts to improve its balance sheet by raising new equity and reducing outstanding liabilities. As a result, NeuroSense shareholders‘ equity now exceeds Nasdaq’s Equity Requirement of at least $2.5 million.
Since the Nasdaq hearing on August 1, 2024, NeuroSense has taken several important steps, including the closing of a $5 million financing in December 2024.
These steps demonstrate NeuroSense’s strong momentum as it prepares to transition into a pivotal Phase 3 study for PrimeC, following the promising results of the Phase 2b PARADIGM study.
